Clinically, a large propensity-matched cohort study involving over 5 million obese patients demonstrated that GLP-1 RA use significantly lowered the risk of developing AD (RR = 0.627), Lewy body dementia (RR = 0.590), and vascular dementia (RR = 0.438) [19]. Here, GLP1R is linked to Alzheimer disease.